Servier, a renowned international pharmaceutical group operating under a foundation, has partnered with IDEAYA Biosciences, a leading precision medicine oncology company, to introduce darovasertib, a promising treatment for uveal melanoma, to patients around the world. This exclusive license agreement grants Servier the regulatory and commercial rights for darovasertib globally, except in the United States, where IDEAYA retains its rights. Darovasertib, a potent protein kinase C (PKC) inhibitor, is positioned to address primary and metastatic uveal melanoma, a rare eye cancer with limited treatment options and a pressing need for improved patient outcomes.
Arnaud Lallouette, the executive vice-president of global medical & patient affairs at Servier, emphasized the company’s dedication to providing transformative therapies to patients with significant medical needs. The collaboration with IDEAYA marks a significant milestone in making darovasertib potentially the first-in-class treatment accessible to uveal melanoma patients worldwide. With a focus on leveraging their global oncology network and expertise in developing targeted oncology therapies, Servier aims to bring this groundbreaking treatment to patients globally.
IDEAYA’s President and CEO, Yujiro S. Hata, expressed confidence in Servier’s global reach and track record in delivering innovative therapies to patients outside the US, ensuring widespread access to this potential life-changing treatment. Daniel Simon, Chief Business Officer at IDEAYA, highlighted that darovasertib is currently undergoing evaluation in multiple global clinical trials, including a phase 2/3 trial in combination with crizotinib for metastatic uveal melanoma and a phase 3 trial for neoadjuvant darovasertib in primary UM. Future plans include a global phase 3 trial in 2026 to evaluate adjuvant darovasertib in primary UM.
Uveal melanoma is a rare and aggressive form of eye cancer that arises in the uveal tract and can metastasize to other parts of the body, predominantly the liver. Despite its rarity, uveal melanoma presents significant risks, necessitating effective treatment options beyond radiation therapy or surgical interventions. Darovasertib has garnered FDA Breakthrough Therapy Designation and Fast Track designation for specific applications in uveal melanoma, underscoring its potential as a pivotal treatment option.
The agreement between IDEAYA and Servier entails an upfront payment of $210 million to IDEAYA, with potential milestone payments of up to $320 million based on regulatory approvals and commercial achievements. IDEAYA will also receive double-digit royalties on net sales outside the United States. Servier will take charge of regulatory and commercial activities globally for darovasertib, with both companies sharing development costs.
Servier, as an independent international pharmaceutical company guided by a nonprofit foundation, is committed to creating a positive social impact on patients and fostering a sustainable world. On the other hand, IDEAYA is dedicated to revolutionizing cancer treatment through precision medicine, focusing on the discovery, development, and commercialization of transformative therapies for cancer patients.
Key Clinical Trials and Development Plans:
- Darovasertib is undergoing evaluation in multiple global clinical trials, including phase 2/3 trials in combination with crizotinib and as a monotherapy for primary UM.
- Future plans include a global phase 3 trial in 2026 to assess adjuvant darovasertib in primary UM, catering to both HLA-A2-negative and -positive patients.
In conclusion, the collaboration between Servier and IDEAYA to develop darovasertib represents a significant advancement in addressing the unmet medical needs of uveal melanoma patients globally. With a strong focus on accelerating the development of this promising treatment through strategic clinical trials and global expansion, both companies are poised to make a profound impact on the field of oncology and improve patient outcomes worldwide.
Tags: regulatory, clinical trials
Read more on pharmabiz.com